[Breaking] Celltrion: "Rekkironaju shows equivalent efficacy against UK variant virus"

[Asia Economy Reporter Chunhee Lee] Seo Jung-jin, Honorary Chairman of Celltrion, announced on the 18th that the company will continue to respond to variant viruses in relation to its COVID-19 antibody treatment 'Rekkironaju (CT-P59)'.

On the same day, Chairman Seo held an online press conference and stated that responses to variant viruses spreading domestically and internationally, such as those from the United Kingdom and South Africa, are already underway.

He explained that the evaluation of neutralizing ability against variant viruses showed that Rekkironaju exhibited the same neutralizing ability against the UK variant virus as it did before the mutation.